Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Estimated
~$10 – $6,250
Mayo ClinicNCT06712810
Phase 1
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred t…
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Estimated
~$10 – $6,250
Baylor College of MedicineNCT06176690
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell P…
Peripheral T-Cell Lymphoma
Estimated
~$10 – $1,125
Associazione Angela Serra per la ricerca sul cancroNCT03964480
Phase 2
A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Estimated
~$10 – $7,500
Seda S. ToluNCT07283822